DE69232387D1 - Kristallinische Oxathiolanderivate - Google Patents

Kristallinische Oxathiolanderivate

Info

Publication number
DE69232387D1
DE69232387D1 DE69232387T DE69232387T DE69232387D1 DE 69232387 D1 DE69232387 D1 DE 69232387D1 DE 69232387 T DE69232387 T DE 69232387T DE 69232387 T DE69232387 T DE 69232387T DE 69232387 D1 DE69232387 D1 DE 69232387D1
Authority
DE
Germany
Prior art keywords
oxathiolane derivatives
crystalline
crystalline oxathiolane
derivatives
oxathiolane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232387T
Other languages
English (en)
Other versions
DE69232387T2 (de
Inventor
Tony Gordon Roberts
Paul Evans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10696001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232387(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE69232387D1 publication Critical patent/DE69232387D1/de
Publication of DE69232387T2 publication Critical patent/DE69232387T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Secondary Cells (AREA)
DE69232387T 1991-06-03 1992-06-02 Kristallinische Oxathiolanderivate Expired - Lifetime DE69232387T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919111902A GB9111902D0 (en) 1991-06-03 1991-06-03 Chemical compounds

Publications (2)

Publication Number Publication Date
DE69232387D1 true DE69232387D1 (de) 2002-03-14
DE69232387T2 DE69232387T2 (de) 2002-09-26

Family

ID=10696001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232387T Expired - Lifetime DE69232387T2 (de) 1991-06-03 1992-06-02 Kristallinische Oxathiolanderivate

Country Status (31)

Country Link
US (1) US5905082A (de)
EP (2) EP0517145B1 (de)
JP (1) JP2851480B2 (de)
KR (1) KR100244008B1 (de)
AP (1) AP300A (de)
AT (1) ATE212630T1 (de)
AU (2) AU656379B2 (de)
BG (1) BG60914B1 (de)
CA (2) CA2311988C (de)
CZ (1) CZ284513B6 (de)
DE (1) DE69232387T2 (de)
DK (1) DK0517145T3 (de)
ES (1) ES2171158T3 (de)
GB (1) GB9111902D0 (de)
GE (1) GEP19991834B (de)
HK (1) HK1009599A1 (de)
IE (2) IE20020782A1 (de)
IL (1) IL102073A (de)
IS (2) IS1867B (de)
MX (1) MX9202619A (de)
NO (1) NO301713B1 (de)
NZ (1) NZ242981A (de)
OA (1) OA09913A (de)
PT (1) PT517145E (de)
RU (1) RU2102393C1 (de)
SG (1) SG52455A1 (de)
SK (1) SK281249B6 (de)
TW (1) TW254939B (de)
UA (1) UA41265C2 (de)
WO (1) WO1992021676A1 (de)
ZA (1) ZA924007B (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4581979A (en) * 1983-07-01 1986-04-15 Automotive Products Plc Shipping and installation restraining clip for master cylinder input member
US6642245B1 (en) 1990-02-01 2003-11-04 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
US20020120130A1 (en) 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
EP0831852B1 (de) 1995-06-07 2006-11-29 Emory University Nucleoside mit anti-hepatitis b virus wirksamkeit
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
CN1228026A (zh) 1996-06-25 1999-09-08 葛兰素集团有限公司 用于治疗hiv感染的含有vx478、叠氮胸苷、ftc和/或3tc的复方制剂
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CN102911166B (zh) * 2001-03-01 2016-08-17 基利得科学公司 顺-ftc的多晶型物及其它晶型
CA2351049C (en) 2001-06-18 2007-03-13 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
WO2003027106A1 (en) * 2001-09-25 2003-04-03 Cadila Healthcar Limited Process for the preparation of crystalline polymorph ii of lamivudine
EP2316468A1 (de) 2002-02-22 2011-05-04 Shire LLC Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
ES2286471T3 (es) * 2002-11-08 2007-12-01 Glaxo Group Limited Composiciones farmaceuticas antivirales.
US20060246130A1 (en) 2003-01-14 2006-11-02 Dahl Terrence C Compositions and methods for combination antiviral therapy
PT1809662E (pt) * 2004-11-10 2009-02-26 Novartis Vaccines & Diagnostic Interferão beta desamidado
US20060242012A1 (en) * 2005-04-22 2006-10-26 Sumit Agarwal Determining or scoring properties to solicit to join ad network using advertiser or aggregated advertiser interest
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ATE485292T1 (de) * 2006-04-18 2010-11-15 Lupin Ltd Neue kristalline form von lamivudin
US20090068267A1 (en) * 2007-09-06 2009-03-12 Combino Pharm, S.L. Novel Pharmaceutical Compositions
WO2009037538A2 (en) * 2007-09-17 2009-03-26 Aurobindo Pharma Ltd Process for the preparation of lamivudine form i
BRPI0820224A2 (pt) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Composto de fórmula iii ou seus estereoisômeros; processo para sua preparação e seu uso; uso de um composto de formula iii(a) ou iii(b) em um processo para a preparação de lamivudina de fórmula i(a) ou um composto de fórmula i(c); processo para preparação de lamivudina de fórmula i(a)
AU2008331168A1 (en) * 2007-11-29 2009-06-04 Ranbaxy Laboratories Limited Crystalline form I of lamivudine and its preparation
SI2225232T1 (sl) * 2007-11-29 2012-12-31 Ranbaxy Laboratories Limited Postopek za pripravo substituiranih 1,3-oksatiolanov
WO2009127996A1 (en) * 2008-04-17 2009-10-22 Ranbaxy Laboratories Limited Novel crystalline form of lamivudine
EP2318398A4 (de) * 2008-09-01 2011-12-07 Hetero Research Foundation Verfahren zur herstellung einer polymorphen form von lamivudin
WO2010055526A1 (en) * 2008-11-12 2010-05-20 Lupin Limited A novel polymorph of emtricitabine and a process for preparing of the same
CN101993439B (zh) * 2009-03-24 2013-04-24 福建广生堂药业股份有限公司 拉米夫定晶型及其制备方法
CN101531656B (zh) * 2009-03-24 2010-12-08 福建广生堂药业有限公司 拉米夫定晶型及其制备方法
US8481554B2 (en) * 2009-05-27 2013-07-09 Hetero Research Foundation Solid oral dosage forms of lamivudine
EP2454244B1 (de) 2009-07-15 2013-06-26 Lupin Limited Verbessertes verfahren zur herstellung von efavirenz
EP2488516B1 (de) 2009-10-14 2015-04-01 Mylan Laboratories Limited Verfahren zur herstellung von lamivudin und neue salze aus seiner herstellung
ES2670811T3 (es) 2010-01-27 2018-06-01 Viiv Healthcare Company Terapia antivírica
WO2011095987A1 (en) * 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
WO2011100381A1 (en) * 2010-02-12 2011-08-18 Merck Sharp & Dohme Corp. Preparation of lamivudine form i
EP2579892A2 (de) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutische immunisierung von hiv-infizierten personen mit stabiler antiretroviraler behandlung
US20130296562A1 (en) 2011-08-05 2013-11-07 Lupin Limited Stereoselective process for preparation of 1,3-oxathiolane nucleosides
WO2013168066A1 (en) 2012-05-05 2013-11-14 Lupin Limited An improved process for the manufacture of lamivudine form i.
CN114099454B (zh) * 2020-08-31 2023-06-27 长春海悦药业股份有限公司 一种拉米夫定片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides

Also Published As

Publication number Publication date
SG52455A1 (en) 1998-09-28
IS1867B (is) 2003-05-02
NO301713B1 (no) 1997-12-01
NO922182D0 (no) 1992-06-02
SK125793A3 (en) 1994-11-09
CA2311988A1 (en) 1992-12-04
CZ284513B6 (cs) 1998-12-16
TW254939B (de) 1995-08-21
RU2102393C1 (ru) 1998-01-20
GB9111902D0 (en) 1991-07-24
ZA924007B (en) 1993-04-28
PT517145E (pt) 2002-07-31
NO922182L (no) 1992-12-04
JP2851480B2 (ja) 1999-01-27
IS4268A (is) 1995-02-27
CA2070230A1 (en) 1992-12-04
WO1992021676A1 (en) 1992-12-10
NZ242981A (en) 1994-04-27
ES2171158T3 (es) 2002-09-01
HK1009599A1 (en) 1999-06-04
IE20020782A1 (en) 2003-04-02
GEP19991834B (en) 1999-11-05
AU656379B2 (en) 1995-02-02
IE921780A1 (en) 1992-12-16
CA2311988C (en) 2005-11-15
JPH06211848A (ja) 1994-08-02
EP0517145B1 (de) 2002-01-30
DE69232387T2 (de) 2002-09-26
SK281249B6 (sk) 2001-01-18
AU1881092A (en) 1993-01-08
CZ261293A3 (en) 1994-04-13
IL102073A (en) 1996-05-14
IS3873A (is) 1992-12-04
CA2070230C (en) 2004-08-03
UA41265C2 (uk) 2001-09-17
US5905082A (en) 1999-05-18
IL102073A0 (en) 1993-01-14
EP0517145A1 (de) 1992-12-09
AP9200395A0 (en) 1992-07-31
ATE212630T1 (de) 2002-02-15
BG60914B1 (bg) 1996-06-28
AU1736192A (en) 1993-03-11
BG98254A (bg) 1994-07-29
MX9202619A (es) 1992-12-01
OA09913A (en) 1994-09-15
DK0517145T3 (da) 2002-05-06
KR100244008B1 (ko) 2000-03-02
EP1099700A1 (de) 2001-05-16
KR930000511A (ko) 1993-01-15
AP300A (en) 1994-01-20

Similar Documents

Publication Publication Date Title
DE69232387D1 (de) Kristallinische Oxathiolanderivate
DE69208877T2 (de) Chinuclidinderivate
DE59208053D1 (de) Oberfräse
DE69218228T2 (de) Polyamid-polyolefin mischungen
FI920718A (fi) Vaetskefoerdelare med indraget foerdelningsmunstycke
FI925763A (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
FI920440A (fi) Squid-maetningsanordning foersedd med skyddsorgan
FI923552A (fi) Smaelt kristalliserad xylitol
DE69216260T2 (de) Piperidinderivate
NO920420D0 (no) 3-quinuklidin-derivater
FI88322B (fi) Med ledbommar foersedd arbetsmaskin
FI925469A (fi) Tiazolylsubstituerade kinolylymetoxifenylaettiksyraderivat
MX9206710A (es) Derivados de piridinol
BR9005812A (pt) Poliimidossiloxanos cristalinos
FI912080A (fi) Lagringslaoda foersedd med en gavelvaeggen slutande genomsynlig klaffskiva
FI920393A (fi) Radio- och landfoerbindelsetelefoner med hands-free-funktion
TR25953A (tr) SüBSTITüE EDILMIS 2-ARILPIROLLER
FI920834A (fi) Med fukos maerkta cytostater
DE69211197T2 (de) 1-Hydroxyvitamin D-Derivate
KR930702353A (ko) 2- 카르바페넴 유도체
TR26694A (tr) SüBSTITüE EDILMIS 4-HETARIL-PIRAZOLINLER
DE69227554D1 (de) Indolinospirobenzopyran-derivate
BG97241A (bg) Триазолпиримидин производни
BR1100452A (pt) Derivados do bifenilmetilimidazol

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 517145

Country of ref document: EP